Morgan Stanley downgrades Novo Nordisk to Underweight
Morgan Stanley cut its rating on Novo Nordisk, citing ongoing concern over semaglutide’s loss of exclusivity overhang. Shares were down more than 1% premarket.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results. The latest changes are still being indexed. Try again shortly for updated results.
Novo Nordisk cut to Underweight by Morgan Stanley
Morgan Stanley downgraded Novo Nordisk from equal-weight to underweight and maintained a $40.00 share price target.